sch 58261 has been researched along with Parkinson Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bohnert, T; Chang, H; Engber, TM; Ensinger, CL; Huang, C; Kumaravel, G; Peng, H; Petter, RC; Sha, L; Van Vlijmen, H; Vu, CB; Wang, J; Whalley, ET; Yao, G | 1 |
| Chang, H; Conlon, PR; Engber, TM; Haque, S; Kiesman, WF; Kumaravel, G; Petter, RC; Sha, L; Wang, J; Whalley, ET; Yao, G | 1 |
| Ayyub, E; Chang, HX; Dowling, JE; Engber, T; Haque, S; Jin, X; Kumaravel, G; Petter, RC; Phadke, D; van Vloten, K; Vessels, JT; Wang, J | 1 |
| Boyle, CD; Chackalamannil, S; Cohen-Williams, ME; Greenlee, WJ; Higgins, GA; Lachowicz, JE; Lankin, CM; Neustadt, BR; Ng, K; Shah, U; Varty, GB; Zhang, H | 1 |
| Arik, L; Boyle, CD; Chackalamannil, S; Foster, C; Greenlee, WJ; Lachowicz, JE; Lindo, N; Monopoli, A; Neustadt, BR; Ng, K; Shah, U; Wang, S; Zhai, Y | 1 |
| Bai, R; Cai, H; Ge, J; He, X; Xie, T; Yao, C; Ye, XY; Zhong, Z; Zhu, J | 1 |
1 review(s) available for sch 58261 and Parkinson Disease
| Article | Year |
|---|---|
Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.
Topics: Biological Products; Blood-Brain Barrier; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Parkinson Disease | 2022 |
5 other study(ies) available for sch 58261 and Parkinson Disease
| Article | Year |
|---|---|
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; Drug Stability; In Vitro Techniques; Male; Mice; Microsomes, Liver; Molecular Structure; Parkinson Disease; Piperazines; Pyrimidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazines; Triazoles | 2004 |
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Cortex; Disease Models, Animal; Mice; Oxidopamine; Parkinson Disease; Pyrazines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain; Cell Membrane; Disease Models, Animal; Parkinson Disease; Pyrazines; Radioligand Assay; Rats; Structure-Activity Relationship | 2005 |
Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Design; Hydrogen-Ion Concentration; Models, Chemical; Parkinson Disease; Pyrimidines; Rats; Solubility; Triazoles; Water | 2008 |
Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Behavior, Animal; Chemistry, Pharmaceutical; Drug Design; Humans; Models, Chemical; Neuroprotective Agents; Parkinson Disease; Piperazines; Pyrimidines; Quinolines; Rats; Structure-Activity Relationship; Triazoles | 2008 |